Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03427034 | Assessment of BladderLight SurvEILlance(ABSEIL) | unknown | Phase 2 / Phase 3 | 2,100 | Cambridge University Hospitals NHS Foundation TrustOTHER | 0 | Feb 9, 2018 | clinicaltrials |
| NCT02072044 | Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy | unknown | Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2017 |
| clinicaltrials |
| NCT03209206 | The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence | unknown | Phase 2 | 84 | Seoul National University HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02740426 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients | unknown | Phase 2 | 200 | Peking University First HospitalOTHER | 1 | Sep 21, 2017 | clinicaltrials |
| NCT02429440 | Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides(UroRCC) | unknown | Phase 1 / Phase 2 | 40 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT02330783 | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | unknown | Phase 2 | 106 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00184015 | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) | unknown | Phase 1 / Phase 2 | 50 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02446795 | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial(QUASAR) | unknown | Phase 1 / Phase 2 | 104 | Consorzio OncotechOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT02923557 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients | unknown | Phase 2 | 200 | Peking University First HospitalOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT02828709 | Safety and Feasibility of IRE for SRMs | unknown | Phase 2 | 20 | Dr. Prof. M.P. Laguna PesOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02360618 | Metformin and Simvastatin Use in Bladder Cancer | unknown | Phase 2 | 44 | London Health Sciences CentreOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT02787915 | DC1s-CTL Cellular Therapy for Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Xuzhou Medical UniversityOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT02774200 | A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients. | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 17, 2016 | clinicaltrials |
| NCT02072031 | Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） | unknown | Phase 2 | 133 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2016 | clinicaltrials |
| NCT02398552 | A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. | unknown | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT01924156 | DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02547350 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas | unknown | Phase 2 | 200 | Xuesong LiOTHER | 0 | Sep 11, 2015 | clinicaltrials |
| NCT02278978 | BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma | unknown | Phase 2 | 129 | National Taiwan University HospitalOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT02422277 | Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy | unknown | Phase 2 | 60 | Mansoura UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00949455 | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium(LaMB) | unknown | Phase 2 / Phase 3 | 204 | Queen Mary University of LondonOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01791387 | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC(DILIGENCE-1) | unknown | Phase 2 | 30 | Auckland District Health BoardOTHER_GOV | 1 | Feb 3, 2015 | clinicaltrials |
| NCT02345499 | Open Versus Laparoscopic Radical Cystectomy(OvsL) | unknown | Phase 2 | 80 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT02324803 | Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | unknown | Phase 2 | 86 | Southern China Urology Cancer ConsortiumOTHER | 1 | Dec 24, 2014 | clinicaltrials |
| NCT01274273 | Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer | unknown | Phase 2 | 118 | University of AarhusOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT02298608 | Efficacy and Safety of IRE for RMs | unknown | Phase 1 / Phase 2 | 10 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01967407 | IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.(IRENE) | unknown | Phase 1 / Phase 2 | 20 | University of MagdeburgOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01487915 | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma(COACH) | unknown | Phase 2 | 80 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01577784 | Pazopanib in Second-line Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 27 | Associació per a la Recerca Oncologica, SpainOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00301990 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | unknown | Phase 2 | 65 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00717587 | Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer | unknown | Phase 2 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00030888 | UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer | unknown | Phase 2 | — | University of California, San FranciscoOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00002846 | Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer | unknown | Phase 2 | 14 | Blumenthal Cancer Center at Carolinas Medical CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00002847 | Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | unknown | Phase 2 | 14 | Blumenthal Cancer Center at Carolinas Medical CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00080977 | High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2 | unknown | Phase 2 | — | Blumenthal Cancer Center at Carolinas Medical CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00093522 | Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer | unknown | Phase 2 | 28 | St. Luke's Medical CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00002589 | Lymphocyte Therapy in Treating Patients With Kidney Cancer | unknown | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00003181 | Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer | unknown | Phase 2 | 35 | Hope Cancer Institute, Inc.INDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00005958 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | unknown | Phase 2 | — | AmgenINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00003604 | Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery | unknown | Phase 2 | 20 | Cancer Biotherapy Research GroupOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00003664 | Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically | unknown | Phase 2 | 30 | Cancer Biotherapy Research GroupOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00293501 | Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery | unknown | Phase 1 / Phase 2 | 35 | University of VermontOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00005038 | Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer | unknown | Phase 2 | — | The Christie NHS Foundation TrustOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00626509 | Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer | unknown | Phase 2 | 110 | Gruppo Italiano Carcinoma RenaleOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00873236 | MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer | unknown | Phase 2 | 30 | Mount Vernon Cancer Centre at Mount Vernon HospitalOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT01222676 | Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder | unknown | Phase 2 | 45 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00027664 | Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer | unknown | Phase 2 | 90 | Cancer Research UKOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT01118039 | Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | unknown | Phase 2 | 41 | Hospital del MarOTHER | 1 | Aug 7, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 9, 2018source: clinicaltrials